Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 48Observational 1

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Other neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1

Interventions

Blood Specimen Collection 53Surveys and Questionnaires 30Drug Therapy 27Immunotherapy 25Surgical Procedures, Operative 22Carboplatin 22Nivolumab 21Immune Checkpoint Inhibitors 20pembrolizumab 18osimertinib 18atezolizumab 17Observation 17Radiotherapy 16Bevacizumab 15Cisplatin 14Afatinib 14Specimen Handling 13Gene Expression Profiling 13Erlotinib Hydrochloride 13lorlatinib 12Pemetrexed 12Magnetic Resonance Spectroscopy 11Ipilimumab 11Immunohistochemistry 11Biopsy 11durvalumab 10alectinib 10Paclitaxel 10Bronchoscopy 10Tomography, X-Ray Computed 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × tremelimumab × Thoracic × Clear all
NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

Cambridge University Hospitals NHS Foundation Trust

Unknown
1,800 enrolled
DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡